Research output: Contribution to journal › Article › Academic › peer-review
Effects of Liraglutide on Myocardial Function After Cardiac Surgery : A Secondary Analysis of the Randomised Controlled GLOBE Trial. / Hulst, Abraham H.; Visscher, Maarten J.; Cherpanath, Thomas G.V. et al.
In: Journal of clinical medicine, Vol. 9, No. 3, 673, 02.03.2020.Research output: Contribution to journal › Article › Academic › peer-review
}
TY - JOUR
T1 - Effects of Liraglutide on Myocardial Function After Cardiac Surgery
T2 - A Secondary Analysis of the Randomised Controlled GLOBE Trial
AU - Hulst, Abraham H.
AU - Visscher, Maarten J.
AU - Cherpanath, Thomas G.V.
AU - van de Wouw, Lieke
AU - Godfried, Marc B.
AU - Thiel, Bram
AU - Gerritse, Bastiaan M.
AU - Scohy, Thierry V.
AU - Bouwman, R. Arthur
AU - Willemsen, Mark G.A.
AU - Hollmann, Markus W.
AU - Devries, J. Hans
AU - Preckel, Benedikt
AU - Hermanides, Jeroen
N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/3/2
Y1 - 2020/3/2
N2 - Introduction: Previous studies demonstrated the cardioprotective properties of glucagon-like peptide-1 receptor agonists in patients with diabetes or cardiac disease. We investigated whether preoperative subcutaneous liraglutide improves myocardial function after cardiac surgery. Methods: We performed a pre-planned secondary analysis of adult patients undergoing cardiac surgery included in the GLOBE trial. Patients were randomised to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg after induction of anaesthesia, or matching placebo. Perioperative echocardiographic assessments, haemodynamic parameters, doses of vasoactive inotropic support and postoperative measurements of troponin, Creatine Kinase-MB, creatinine and lactate were compared between groups. Results: The study population consisted of the entire intention-to-treat cohort of the GLOBE trial. In this study, 129 patients received liraglutide and 132 patients placebo. Baseline characteristics were comparable between groups. Postoperatively, 170 (65%) patients underwent echocardiography. In the liraglutide group, more patients had a normal left ventricular systolic function (68%, 59 patients) compared to placebo (53%, 44 patients), difference = 15%, 95%CI = 0–30, p = 0.049. Assessment of the right ventricle revealed no difference in function. Conclusions: Patients receiving short-term preoperative liraglutide treatment better maintained normal myocardial function after cardiac surgery. This study warrants further evaluation of the potential beneficial effects of GLP-1 receptor agonists in cardiac surgery patients.
AB - Introduction: Previous studies demonstrated the cardioprotective properties of glucagon-like peptide-1 receptor agonists in patients with diabetes or cardiac disease. We investigated whether preoperative subcutaneous liraglutide improves myocardial function after cardiac surgery. Methods: We performed a pre-planned secondary analysis of adult patients undergoing cardiac surgery included in the GLOBE trial. Patients were randomised to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg after induction of anaesthesia, or matching placebo. Perioperative echocardiographic assessments, haemodynamic parameters, doses of vasoactive inotropic support and postoperative measurements of troponin, Creatine Kinase-MB, creatinine and lactate were compared between groups. Results: The study population consisted of the entire intention-to-treat cohort of the GLOBE trial. In this study, 129 patients received liraglutide and 132 patients placebo. Baseline characteristics were comparable between groups. Postoperatively, 170 (65%) patients underwent echocardiography. In the liraglutide group, more patients had a normal left ventricular systolic function (68%, 59 patients) compared to placebo (53%, 44 patients), difference = 15%, 95%CI = 0–30, p = 0.049. Assessment of the right ventricle revealed no difference in function. Conclusions: Patients receiving short-term preoperative liraglutide treatment better maintained normal myocardial function after cardiac surgery. This study warrants further evaluation of the potential beneficial effects of GLP-1 receptor agonists in cardiac surgery patients.
KW - Cardiac function
KW - CK-MB
KW - Echocardiography
KW - Left ventricular function
KW - Liraglutide
KW - Placebo
KW - Randomised controlled trial
KW - Troponin
UR - http://www.scopus.com/inward/record.url?scp=85097898779&partnerID=8YFLogxK
U2 - 10.3390/jcm9030673
DO - 10.3390/jcm9030673
M3 - Article
C2 - 32131527
VL - 9
JO - Journal of clinical medicine
JF - Journal of clinical medicine
SN - 2077-0383
IS - 3
M1 - 673
ER -
ID: 15530112